Over the last 5 years, prophylactic vaccination against human papillomavirus (HPV) in pre-
adolescent females has been introduced in most developed countries, supported by …

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

Background Adequate coverage is key to the success of human papillomavirus (HPV)
vaccination programmes. There is currently no organised HPV vaccination programme in …

Introduction. Cervical cancer is caused by infection with human papillomavirus (HPV).
Several countries have implemented vaccination programs against HPV for teenage girls …

Background Streptococcus pneumoniae causes morbidity and mortality among all ages in
The Netherlands. To reduce this burden, infants in The Netherlands receive the 10-valent …

The AS04-adjuvanted human papillomavirus (HPV) 16/18 vaccine (Cervarix®) is a
noninfectious recombinant vaccine produced using purified virus-like particles (VLPs) that …

Background: Vaccination against human papillomavirus (HPV) types 16/18 is being
implemented in many countries. There may be indirect benefit of HPV vaccination to …

Objective: Recently, a vaccine with the capacity to protect against serogroup B
meningococcal (MenB) disease received a positive opinion of the European Medicines …

Background Vaccinating girls against human papillomavirus (HPV) infection is a highly
effective and cost-effective intervention to provide protection against HPV-induced cancers …

Background Infection with HPV 16 and 18, the major causative agents of cervical cancer,
can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines …